Lantheus Holdings, INC

Lantheus Holdings, Inc. announced its second quarter 2026 financial results and a definitive agreement to be acquired by Curium US Holdings LLC for up to $8.0 billion.

Curium and Lantheus Holdings, Inc. have entered into a definitive agreement for Curium to acquire Lantheus in a cash and stock deal valued at up to $8 billion.

Lantheus Holdings announced first quarter 2026 financial results, with worldwide revenue reaching $377.3 million, while also receiving FDA approvals for key products.

Lantheus Holdings shareholders approved the 2026 Equity Incentive Plan and a board declassification amendment at the 2026 Annual Meeting.

Lantheus Holdings, Inc. announced its fourth quarter and full year 2025 financial results, revealing a strategic pivot towards innovative radiodiagnostics and lower 2026 guidance.

Lantheus Holdings, Inc. details CEO Brian Markison's retirement plan, including a consulting agreement and separation terms.

Lantheus Holdings reports Q2 2026 revenue growth driven by key products, while navigating a pending acquisition and regulatory updates.

Lantheus Holdings reported a 1.2% increase in revenue for the first quarter of 2026, driven by strong performance in Neuraceq and DEFINITY, despite a decrease in PYLARIFY sales.

Lantheus Holdings, Inc. reported a significant drop in Q3 net income and diluted EPS, driven by increased operating expenses and strategic investments, despite slight revenue growth.

Lantheus Holdings reports mixed Q2 2025 results with revenue declines in key products offset by strategic acquisitions and pipeline advancements.

Lantheus Holdings' Q1 2025 results show slight revenue growth, strategic moves in radiopharmaceuticals, and a focus on oncology and neurology.

Lantheus Holdings saw a significant increase in revenue and strategic expansion through acquisitions in the third quarter of 2024, primarily driven by PYLARIFY and DEFINITY sales.

Lantheus Holdings, Inc. reports strategic divestitures, key acquisitions, and pipeline advancements in 2025, alongside leadership changes and PYLARIFY revenue adjustments.

Lantheus Holdings' 2024 10-K filing highlights strategic acquisitions, revenue growth driven by PYLARIFY and DEFINITY, and ongoing clinical development programs.

Lantheus Holdings announces a CEO succession plan, strategic agreements with Perspective Therapeutics, and positive topline results for PNT2002, while navigating a complex regulatory and competitive landscape.

Ludger Dinkelborg, See Remarks of Lantheus Holdings, Inc., reported a transaction in 2,536 shares of common stock on August 17, 2026.

Kimberly Brown, Chief Accounting Officer of Lantheus Holdings, Inc., reported a transaction in 463 shares of common stock on August 17, 2026.

Director Gerard Ber of Lantheus Holdings, Inc. reported a transaction involving the acquisition of common stock.

Mary Anne Heino, Executive Chair and CEO of Lantheus Holdings, Inc., reported transactions involving common stock on May 14, 2026.

Director Julie McHugh acquired 4,137 shares of Lantheus Holdings common stock on May 14, 2026, increasing her direct beneficial ownership.

Lantheus Holdings Director Phuong Khanh Morrow acquired 4,137 shares of common stock on May 14, 2026.

Lantheus Holdings, Inc. details strategic acquisitions, pipeline advancements, and corporate governance updates in its 2026 Proxy Statement, emphasizing a focus on radiodiagnostics and long-term value creation.

Lantheus Holdings will hold its annual stockholders meeting on May 1, 2025, to vote on director elections, executive compensation, auditor ratification, and a shareholder proposal regarding board declassification.

Lantheus Holdings announces record revenue and strong free cash flow in 2024, driven by PYLARIFY and DEFINITY, and outlines strategic investments in neurology and oncology for future growth.

Lantheus Holdings will hold its annual stockholders meeting on April 25, 2024, to vote on director elections, executive compensation, an equity incentive plan amendment, and auditor ratification.

Lantheus Holdings' 2024 proxy statement highlights a year of robust financial performance, strategic portfolio expansion, and a commitment to sustainable shareholder value, alongside key governance proposals for the upcoming annual meeting.

Farallon Capital Management, L.L.C. and affiliated entities have reported beneficial ownership of 8.6% of Lantheus Holdings, Inc. common stock as of June 30, 2026.

Vanguard Portfolio Management has reported a beneficial ownership stake of 5.06% in Lantheus Holdings Inc., as of June 30, 2026.

Janus Henderson Group plc has reported a 7.4% beneficial ownership stake in Lantheus Holdings, Inc. as of March 31, 2026.

Vanguard Capital Management reports beneficial ownership of over 3.4 million shares, representing 5.25% of Lantheus Holdings' common stock.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Lantheus Holdings Inc. following an internal realignment.

Morgan Stanley and its subsidiary have reported reducing their beneficial ownership in Lantheus Holdings, Inc. to below the 5% threshold.